Risk-based treatment approaches for neuroblastoma have been ongoing for decades.
However, the criteria used to define risk in various institutional and cooperative groups were …

Neuroblastoma (NB), the most common extracranial tumor of childhood, is a cancer of
primordial neural crest cells that give rise to sympathetic neural ganglia and adrenal …

PURPOSE Treatment planning for children with neuroblastoma requires accurate
assessment of prognosis. The most recent Children's Oncology Group (COG) risk …

Background Gene expression profiling is being widely applied in cancer research to identify
biomarkers for clinical endpoint prediction. Since RNA-seq provides a powerful tool for …

Estimated 5‐year survival rates for patients with non‐high‐risk and high‐risk neuroblastoma
are 90% and 50%, respectively. Recent clinical trials have shown excellent outcomes with …

Amplification of MYCN is a driver mutation in a subset of human neuroendocrine tumors,
including neuroblastoma. No small molecules that target N-Myc, the protein encoded by …

Purpose Children diagnosed at age≥ 18 months with metastatic MYCN-nonamplified
neuroblastoma (NBL-NA) are at high risk for disease relapse, whereas those diagnosed at …

Neuroblastoma is an embryonal malignancy of the sympathetic nervous system.
Spontaneous regression and differentiation of neuroblastoma is observed in a subset of …

Purpose The primary objective of Children's Oncology Group study P9641 was to
demonstrate that surgery alone would achieve 3-year overall survival (OS)≥ 95% for …

Neuroblastoma (NB) is the most common pediatric tumor malignancy that originates from the
neural crest and accounts for more than 15% of all the childhood deaths from cancer. The …